Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?

New data from J&J's cardiovascular outcomes trials shows leg and foot amputations occurred about twice as often in diabetes patients treated with canagliflozin versus placebo.

FDA is requiring a boxed warning on Johnson & Johnson's Invokana (canagliflozin), Invokamet (canagliflozin/metformin) and Invokamet XR labeling about the increased risk of leg and foot amputations in patients taking the diabetes medicines.

The agency issued a safety announcement May 16 confirming the risk based on new data from J&J's two...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet